logo
The strategies Australians are using to avoid Jim Chalmers' new super tax

The strategies Australians are using to avoid Jim Chalmers' new super tax

The Australian Business Network
While the federal government hopes to add $2.3bn per year to its coffers from the incoming super tax, savvy Australians are preparing to implement strategies via self managed super funds (SMSFs) to circumvent its impact. It may leave the government well short of its $40bn collection target over the next decade.
When federal parliament resumes later this month Labor will welcome three extra senators, boosting their numbers to 29. And with 10 green senators and a further 10 crossbenchers, the government will have multiple pathways to get the required 39 votes needed to pass the contentious Div 296 superannuation tax on super balances above $3m.
With the commencement of this new tax on unrealised gains looking more like a case of 'when' rather than 'if', Sydney-based accountant Timothy Ricardo from Accounting Advisor Group says that the key to overcoming Div 296 tax is to bring forward family succession planning arrangements.
'Rather than wait until death to transfer wealth to the next generation, a retiree with over $3m in a self managed super fund might consider adding their children to the fund and start to build their member balance now,' Ricardo says.
The way this would work is that the retiree would withdraw a tax-free lump sum from their account-based pension and gift it to the child. The child would then contribute the amount back to the SMSF as a non-concessional contribution. By utilising bring forward rules, the maximum a child could contribute to super is $360,000 in one financial year.
'For someone with $3.5m in super and two children, withdrawing two lots of $360,000 and having the children contribute it back to the SMSF, this would reduce the member balance out of the danger zone of Div 296 to $2.78m while the overall fund balance would remain at $3.5m' Ricardo says.
Although the children would be in the accumulation phase and their member balance taxed at up to 15 per cent on income and gains, it sidesteps the annual taxing of unrealised capital gains under Div 296 tax. It was only in 2021 that the Morrison government increased the maximum number of SMSF members from 4 to 6, which conveniently allows more children and family members to participate in this strategy. What you need to know to beat Div 296
The first is that you must have reached a condition of release to be able to withdraw lump sum amounts from super. This usually means reaching age 60 and having retired. For people aged between 60 to 64 who are still working, a transition to retirement pension can be established and up to 10 per cent of the balance withdrawn each financial year as a pension payment.
You also need to have a high level of trust that your child or family member will contribute the funds you gift them back to the SMSF rather than take the money and run. And to state the obvious, even when contributed back to the SMSF by the child, it forms part of their members balance, which may be inaccessible for decades if the child is aged in their 30's or 40's.
Administratively, as each member of a SMSF must also be a trustee, the operation of the fund becomes more complex. All trustees will be required to sign off on documents such as the investment strategy review, minutes, resolutions, financial statements and tax return.
The final challenge is having sufficient liquidity within the super fund to make withdrawals to give to your children. Although this may seem like a deal breaker for those with lumpy assets in the SMSF such as the 17,000 farmers with primary production land inside of SMSF, a recycling strategy can be executed which achieves the goal of transitioning super out of the higher balance parent's name into the lower balance child's name.
Ricardo explains the circular nature of the strategy: 'Say a 65 year old retired farmer with a $4m farm in their SMSF only has $100,000 in the fund bank account. To build the member balance of the children, the farmer can withdraw the $100,000 cash from the fund, give it to the child who then contributes it back in the fund, replenishing the $100,000 SMSF bank account balance. This process can then be repeated over and over again until either contribution caps are reached for the child or the desired level of dilution of the parents member balance has been achieved.'
It is important to remember that although much has been spoken about the new super tax and its adverse consequences for people with more than $3m in super, its wording has yet to be finalised. Labor does not have a majority in the senate and they may need to compromise with the Greens or crossbenchers, which could see amendments to the final bill. As such, the advice coming from tax, legal and financial advisors is to prepare strategies to mitigate the Div 296 tax, however keep them on ice until the final legislation is passed and comes into effect.
James Gerrard is principal and director of financial planning firm www.financialadvisor.com.au Read related topics: Wealth James Gerrard Wealth Columnist
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

NeuroScientific locks in deal to scale-up stem cell production
NeuroScientific locks in deal to scale-up stem cell production

Sydney Morning Herald

time29 minutes ago

  • Sydney Morning Herald

NeuroScientific locks in deal to scale-up stem cell production

Perth-based stem cell therapy pioneer NeuroScientific Biopharmaceuticals has started transferring its patented StemSmart process to one of Australia's biggest and most experienced cell therapy manufacturers to scale up clinical-grade production. Queensland-based Q-Gen Cell Therapeutics will take over the manufacturing of StemSmart's specific mesenchymal stromal stem cells (MSC) from Royal Perth Hospital's Cell and Tissue Centre. NeuroScientific says the technology transfer will allow it to establish MSC manufacturing for its StemSmart infusions for further clinical trials and pursue commercial opportunities. The MSC technology was developed as a last-line infusion treatment for critically ill patients, including those experiencing severe immune complications from bone marrow transplants, kidney and lung transplant rejection and inflammatory Crohn's disease. 'This relationship will allow the company to scale the manufacturing of its StemSmart technology.' NeuroScientific Biopharmaceuticals chief executive officer Nathan Smith NeuroScientific acquired the StemSmart technology in late June via its $4.1 million acquisition of unlisted Perth-based stem cell company Isopogen. Isopogen had previously signed a manufacturing contract with QIMR Berghofer, under which Q-Gen undertook manufacturing process development to scale up clinical-grade production of the StemSmart platform. Q-Gen, located in QIMR in Brisbane, has more than 25 years of experience in cell therapy manufacturing for industry. The laboratory specialises in manufacturing cellular immunotherapies for national and international clinical trials from 13 cleanrooms dedicated to cell manufacturing and quality control. NeuroScientific Biopharmaceuticals chief executive officer Nathan Smith said: 'We are very pleased to be partnering with Q-Gen given their extensive experience in manufacturing, process development and GMP production of biologic products for clinical trials. This relationship will allow the company to scale the manufacturing of its StemSmart technology to address substantial market opportunities.' StemSmart offers a step up from traditional MSC manufacturing in that the cells are grown in a special medium, becoming activated in the process. The platform technology was developed at Royal Perth Hospital and manufactured using the hospital's processes.

NeuroScientific locks in deal to scale-up stem cell production
NeuroScientific locks in deal to scale-up stem cell production

The Age

time29 minutes ago

  • The Age

NeuroScientific locks in deal to scale-up stem cell production

Perth-based stem cell therapy pioneer NeuroScientific Biopharmaceuticals has started transferring its patented StemSmart process to one of Australia's biggest and most experienced cell therapy manufacturers to scale up clinical-grade production. Queensland-based Q-Gen Cell Therapeutics will take over the manufacturing of StemSmart's specific mesenchymal stromal stem cells (MSC) from Royal Perth Hospital's Cell and Tissue Centre. NeuroScientific says the technology transfer will allow it to establish MSC manufacturing for its StemSmart infusions for further clinical trials and pursue commercial opportunities. The MSC technology was developed as a last-line infusion treatment for critically ill patients, including those experiencing severe immune complications from bone marrow transplants, kidney and lung transplant rejection and inflammatory Crohn's disease. 'This relationship will allow the company to scale the manufacturing of its StemSmart technology.' NeuroScientific Biopharmaceuticals chief executive officer Nathan Smith NeuroScientific acquired the StemSmart technology in late June via its $4.1 million acquisition of unlisted Perth-based stem cell company Isopogen. Isopogen had previously signed a manufacturing contract with QIMR Berghofer, under which Q-Gen undertook manufacturing process development to scale up clinical-grade production of the StemSmart platform. Q-Gen, located in QIMR in Brisbane, has more than 25 years of experience in cell therapy manufacturing for industry. The laboratory specialises in manufacturing cellular immunotherapies for national and international clinical trials from 13 cleanrooms dedicated to cell manufacturing and quality control. NeuroScientific Biopharmaceuticals chief executive officer Nathan Smith said: 'We are very pleased to be partnering with Q-Gen given their extensive experience in manufacturing, process development and GMP production of biologic products for clinical trials. This relationship will allow the company to scale the manufacturing of its StemSmart technology to address substantial market opportunities.' StemSmart offers a step up from traditional MSC manufacturing in that the cells are grown in a special medium, becoming activated in the process. The platform technology was developed at Royal Perth Hospital and manufactured using the hospital's processes.

NeuroScientific locks in deal to scale-up stem cell production
NeuroScientific locks in deal to scale-up stem cell production

West Australian

time29 minutes ago

  • West Australian

NeuroScientific locks in deal to scale-up stem cell production

Perth-based stem cell therapy pioneer NeuroScientific Biopharmaceuticals has started transferring its patented StemSmart process to one of Australia's biggest and most experienced cell therapy manufacturers to scale up clinical-grade production. Queensland-based Q-Gen Cell Therapeutics will take over the manufacturing of StemSmart's specific mesenchymal stromal stem cells (MSC) from Royal Perth Hospital's Cell and Tissue Centre. NeuroScientific says the technology transfer will allow it to establish MSC manufacturing for its StemSmart infusions for further clinical trials and pursue commercial opportunities. The MSC technology was developed as a last-line infusion treatment for critically ill patients, including those experiencing severe immune complications from bone marrow transplants, kidney and lung transplant rejection and inflammatory Crohn's disease. NeuroScientific acquired the StemSmart technology in late June via its $4.1 million acquisition of unlisted Perth-based stem cell company Isopogen. Isopogen had previously signed a manufacturing contract with QIMR Berghofer, under which Q-Gen undertook manufacturing process development to scale up clinical-grade production of the StemSmart platform. Q-Gen, located in QIMR in Brisbane, has more than 25 years of experience in cell therapy manufacturing for industry. The laboratory specialises in manufacturing cellular immunotherapies for national and international clinical trials from 13 cleanrooms dedicated to cell manufacturing and quality control. StemSmart offers a step up from traditional MSC manufacturing in that the cells are grown in a special medium, becoming activated in the process. The platform technology was developed at Royal Perth Hospital and manufactured using the hospital's processes. The cells have been used many times over the years via early-phase clinical trials, studies and on compassionate grounds, with promising results. Later in the year, NeuroScientific expects to receive the interim results from its latest compassionate access program involving patients with difficult-to-treat fistulising Crohn's disease, in which an open wound develops from a gut flare-up that extends out to the skin. A successful clinical outcome will help the company validate its proprietary StemSmart technology in this patient group, which otherwise has limited treatment options. NeuroScientific is fast building towards regulatory approvals and commercialisation for StemSmart. This month, it announced two heavy-hitting appointments. The company has appointed Melbourne-based Smith's as its chief executive officer and well-regarded Perth-based paediatric haematologist and oncologist Dr Catherine Cole as its chief medical officer. Smith has extensive experience in cell and gene therapies in senior commercial, operational and strategic roles in Australia and the United States, which should prove invaluable as the company navigates the regulatory and commercial pathways for its innovative StemSmart technology. The company says Smith's deep expertise in good manufacturing practice (GMP) will be critical for converting the biotechnology startup into a scaled-up commercial stem cell company. Cole has held clinical and academic leadership roles across Australia and overseas, including head of haematology and oncology at Perth Children's Hospital and professor of paediatric haematology and oncology at The University of Western Australia. She is also the former director of stem cell transplantation at Perth Children's Hospital, placing her front and centre in NeuroScientific's race to employ stem cell therapy to treat some of the most debilitating transplant complications and autoimmune diseases. The high-level executive duo join a strong leadership team, which also includes Perth-based haematology medical scientist Dr Marian Sturm as NeuroScientific's chief scientific officer. Sturm pioneered the use of the MSC used in StemSmart over the past 20 years in her former role as facility director of Royal Perth Hospital's Cell and Tissue Therapies centre. While competition in the stem cell space is fierce, the upside is enormous. StemSmart's progress and results over decades of development position the product closer to near-term commercialisation than some others also in the pipeline, which will be helped along by NeuroScientific's healthy bank balance. A $3.5 million capital raise handed the company a $7.5 million war chest to support further trials and development and help it generate plenty of momentum towards its long-term goal of partial or full registration for StemSmart, first up as a Crohn's treatment. NeuroScientific's progress in the field of stem cell therapy has certainly got the tongues wagging recently. The soaring share price has hardly taken a breather, clocking in with an eye-watering 360 per cent rise to 23.5 cent a share in the last two months alone. As StemSmart edges closer to regulatory approval and potential commercial rollout starts to take shape - starting with the pressing need in Crohn's disease - NeuroScientific appears poised to carve out a meaningful niche in the high-stakes world of advanced cell therapies. Is your ASX-listed company doing something interesting? Contact:

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store